Astria Therapeutics, Inc. — Director's Dealing 2016

Feb 17, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATABASIS PHARMACEUTICALS INC (CATB)
CIK: 0001454789
Period of Report: 2016-02-11

Reporting Person: Donovan Joanne M. (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-11	Stock Option (right to buy)	$4.57	A	66000	Acquired	2026-02-10	Common Stock (66000)	Direct

Footnotes

F1: This option was granted on February 11, 2016 and is scheduled to vest over four years, with 25% of the shares vesting on the first anniversary of February 11, 2016 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.